Skip to main content

Table 7 Whole blood (A), renal function (B), biochemical results (C) and hepatic function (D) of the patients who took BCc1 nanomedicine revealed that none of the patients suffered deficiency

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Index Unit Amount
(A) Whole blood function
WBC ×1000/mm3 5.1 ± 1.3
RBC Mill/mm3 4.4 ± 0.6
HGB g/dl 12.5 ± 1.8
HCT % 40.1 ± 4.5
MCV Fl 88.4 ± 10.2
MCH pg 28.8 ± 4.3
MCHC g/dl 32.9 ± 1.8
Platelet ×1000/mm3 195 ± 27
RDW   43 ± 21.1
PDW Fl 13.3 ± 0.8
MPV Fl 10 ± 1.6
(B) Renal function
Urea mg/dl 30.4 ± 13.6
Creatinine mg/dl 1.0 ± 0.1
(C) Biochemical function
Iron µg/dl 56 ± 15
TIBC µg/dl 314 ± 30
UIBC µg/dl 258 ± 10
Ferritin ng/dl 250 ± 80
Sodium mmol/l 139 ± 7
Potassium mmol/l 4.1 ± 0.7
Chloride mmol/l 105 ± 10
(D) Hepatic function
Triglycerides mg/dl 102 ± 48
Total cholesterol mg/dl 183 ± 22
AST (SGOT) U/l 19.1 ± 5.1
ALT (SGPT) U/l 14.3 ± 4.3
Alkaline phosphatase IU/l 286.6 ± 95
Bilirubin (total) mg/dl 0.725 ± 0.09
Bilirubin (direct) mg/dl 0.2 ± 0.1